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In vivo imaging of pathological protein aggregates
provides essential knowledge of the kinetics and
implications of these lesions in the progression of
proteopathies, such as Alzheimer disease. Lumines-
cent conjugated oligothiophenes are amyloid-spe-
cific ligands that bind and spectrally distinguish
different types of amyloid aggregates. Herein, we
report that heptamer formyl thiophene acetic acid
(hFTAA) passes the blood-brain barrier after systemic
administration and specifically binds to extracellular
-amyloid deposits in the brain parenchyma (A
plaques) and in the vasculature (cerebral -amyloid
angiopathy) of -amyloid precursor protein trans-
genic APP23 mice. Moreover, peripheral application
of hFTAA also stained intracellular lesions of hyper-
phosphorylated Tau protein in P301S Tau transgenic
mice. Spectral profiling of all three amyloid types was
acquired ex vivo using two-photon excitation. hFTAA
revealed a distinct shift in its emission spectra when
bound to A plaques versus Tau lesions. Furthermore,
a spectral shift was observed for A plaques versus
cerebral -amyloid angiopathy, indicating that differ-
ent amyloid types and structural variances of a specific
amyloid type can be distinguished. In conclusion, by
adding spectral signatures to amyloid lesions, our re-
sults pave the way for a new area of in vivo amyloid
imaging, allowing in vivo differentiation of amyloid
(sub)types and monitoring changes of their struc-ture/composition over time. (Am J Pathol 2012, 181:
1953–1960; http://dx.doi.org/10.1016/j.ajpath.2012.08.031)
Amyloidosis is a common pathological hallmark of most
age-related neurodegenerative diseases.1,2 Each dis-
ease is characterized by the deposition of one or several
proteins in the amyloid state in which they form elon-
gated, unbranched fibers, with a core consisting of many
stranded -sheets. All amyloids share a common three-
dimensional structure with similar chemical and biophys-
ical properties.3 Thereby, amyloids are specifically rec-
ognized by hydrophobic dyes, such as Congo red and
thioflavin T,4,5 that historically have been used for the
histopathological diagnosis of amyloid diseases. On
binding to amyloid, Congo red reveals a typical apple
green birefringence (anomalous colors) under polarized
light, whereas the fluorescence intensity of thioflavin T
strongly increases on amyloid binding.6
More recently, Congo red and thioflavin T derivatives
have been developed for in vivo amyloid imaging. For
example, in Alzheimer disease (AD), Pittsburgh Com-
pound B is used for the detection of A deposits with
positron emission tomography.7 Pittsburgh Compound
B–positron emission tomography imaging is thought to
predict AD disease progression from a presymptomatic
phase to symptomatic AD.8,9 Methoxy-X04 has been
used for multiphoton in vivo imaging of A lesions in
experimental mouse models,10,11 and such imaging
studies have greatly contributed to a better understand-
ing of the dynamics of A plaque formation and growth.12
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applied peripherally [ie, they cross the blood-brain bar-
rier (BBB) reasonably well].
Despite the tremendous progress of in vivo amyloid
imaging, several hurdles remain. Given the mixed path-
ological characteristics of most cerebral amyloidoses
and the increasing interest in particular conformational
variants (amyloid strains) with potentially diverse dif-
ferent biological activities, there is great demand to
dissociate the various amyloid lesions and amyloid
(sub) types.3,13–15 AD, for example, is characterized by
amyloid lesions in forms of extracellular A plaques and
intracellular Tau aggregates, so-called neurofibrillary tan-
gles.16 In addition, patients with AD frequently exhibit A
deposition in the vasculature, a feature known as cere-
bral -amyloid angiopathy (CAA).17 Dyes that could
discriminate between those lesions would be of enor-
mous scientific and diagnostic value.
A novel group of amyloid-specific ligands that can
provide a unique spectral signature for distinct amyloid
structures has recently been developed.18 Luminescent
conjugated polythiophenes (LCPs) and luminescent con-
jugated oligothiophenes (LCOs) possess a flexible
backbone that can adapt its conformation on binding
to the respective amyloid target. Because this structural
twist results in a change in the spectral properties, subtle
differences in amyloid conformation/structure can be vi-
sualized using one identical probe. Different conforma-
tional states of A deposits could be visualized by ap-
plying LCPs to histological postmortem preparations.19
Moreover, A deposits could be separated from neurofi-
brillary tangles on human AD autopsy tissue.20 LCPs
have also differentiated multiple prion strains on histolog-
ical stainings.21
The aim of the present study was to further exploit
these amyloid ligands and to transfer their implications
into an in vivo setting. We thereby identified an LCO,
hFTAA,20 that fulfilled all necessary requirements for in
vivo spectral amyloid imaging.
Materials and Methods
Mice
Aged depositing APP23 mice,22 overexpressing human
APP with the Swedish double mutation (K670N/M671L),
were used to evaluate the staining of A plaques and
CAA. Aged hemizygous and homozygous P301S Tau
transgenic (tg) mice,23 expressing human Tau with the
P301S single mutation, were used to study the staining
capacities for Tau aggregates. Both lines express the
transgene under the control of the neuron-specific murine
Thy-1 promoter element and were on a C57BL/6J back-
ground. Crosses of the two lines (hemizygous for both
transgenes) were used to obtain mice with mixed patho-
logical characteristics. Non-transgenic animals were
used as controls. All procedures with animals were per-
formed in compliance with protocols approved by the
local animal use committee and university regulations.In Vivo Labeling and Tissue Processing
Mice were i.v. injected once in the lateral tail vein with 20
mg/kg of the heptameric luminescent conjugated oligo-
thiophene hFTAA,20 dissolved at 5 mg/mL in PBS (the
chemical structure of hFTAA is depicted in Figure 1). At
24 hours after injection, mice were sacrificed. For spec-
tral analysis, one brain hemisphere was gently snap fro-
zen by immersion in a 2-methylbutane bath surrounded
by dry ice and stored at 80°C until it was coronally cut
on a cryostat (Microm, Walldorf, Germany) in sections (25
m thick) mounted on superfrost slides (R. Langen-
brinck, Emmendingen, Germany). Slides were dried at
room temperature and finally stored at 80°C. The day
before spectral image acquisition, slides were thawed,
dried at room temperature, and mounted with Fluores-
cence Mounting Medium (Dako, Carpentaria, CA). For
overview images or immunohistochemical (IHC) staining,
the other brain hemisphere was fixed in 4% paraformal-
dehyde in PBS for 2 days at 4°C, subsequently cryopro-
tected in 30% sucrose for another 2 days at 4°C, and
frozen in 2-methylbutane. Coronal sections (40 m thick)
were taken using a freezing/sliding microtome (Leica,
Nussloch, Germany). Sections were stored in cryopro-
tectant solution (25% glycerol and 30% ethylene glycol in
0.1 mol/L phosphate buffer) at 20°C. Before staining or
mounting, sections were thoroughly washed in PBS.
Ex Vivo Colocalization with Antibodies against
A and Tau Lesions
Paraformaldehyde-fixed sections of hFTAA-injected mice
were used for subsequent IHC labeling of A and Tau
aggregates using standard fluorescent immunolabeling
procedures. For the non-fluorescence visualization of the
A signal, standard immunoperoxidase procedures were
performed using an Elite ABC kit (Vector Laboratories,
Burlingame, CA) and Vector SG (Vector Laboratories) as
a substrate. In general, A deposits were stained using
the polyclonal antibody CN3 (1:1000) raised against syn-
thetic human A1–16 peptide.24 Hyperphosphorylated
Tau was detected with the monoclonal antibody AT100,
specific to Tau phosphorylated at Ser212 and Thr214
(1:2000; Autogen Bioclear, Calne, UK). Alexa Fluor 633
goat anti-rabbit or goat anti-mouse IgGs (Invitrogen,
Karlsruhe, Germany) were used as secondary antibod-
ies, respectively. In contrast to CN3 labeling, Tau staining
required an additional antigen retrieval step in 10 mmol/L
citrate buffer (1.8 mmol/L citric acid and 8.2 mmol/L triso-
dium citrate, pH 6.0) at 90°C for 35 minutes. A semiquan-
titative analysis was performed to estimate the percent-
Figure 1. Chemical structure of the sodium salt of hFTAA.age of overlap between hFTAA and AT100 labeling.
Amyloid Distinction with LCOs 1955
AJP December 2012, Vol. 181, No. 6Therefore, Tau labeling in the neocortex was analyzed on
double-labeled sections (25 m thick), two for each of the
four P301S Tau tg mice (see Results for mice details).
Two-channel images were acquired for randomly se-
lected cortical AT100-positive cells. Image acquisition
was performed at the Axioplan 2 fluorescent microscope
coupled to a b/w MRm Axiocam (Carl Zeiss MicroImag-
ing GmbH, Jena, Germany) using the YFP filter set (BP
500/20 for excitation and BP 535/30 for emission; AHF
Analysentechnik, Tübingen, Germany) for hFTAA and the
Cy5 filter set (BP 640/30 for excitation and BP 690/50 for
emission; Carl Zeiss MicroImaging GmbH) for Alexa 633.
After acquisition, all AT100-positive cells were visually
examined for potential double labeling with hFTAA (in
total, 198 cells were studied).
Histological Staining with Amyloidotropic Dyes
Staining with hFTAA (1.5 mmol/L in deionized water, di-
luted 1:500 in PBS) was performed similar to a previous
description.20 Staining with thioflavin S and Congo red
was performed according to standard protocols. Staining
with methoxy-X04 included incubation with a staining so-
lution of 4% vol of 10 mg/mL methoxy-X0410 in dimethyl
sulfoxide and 7.7% vol CremophorEL (Sigma-Aldrich,
Steinheim, Germany) in 88.3% vol PBS for 30 minutes at
room temperature.
Image Acquisition
Mosaic overview images of hFTAA-injected mouse sec-
tions were acquired on a Zeiss Axioplan 2 fluorescent
microscope with AxiocamMRm (Carl Zeiss MicroImaging
GmbH) using the YFP filter set (BP 500/20 for excitation
and BP 535/30 for emission; AHF Analysentechnik) and a
10/0.3 air Plan Neofluar objective (Carl Zeiss MicroIm-
aging GmbH) in combination with the MosaiX function of
the Axiovision 4.7 software (Carl Zeiss MicroImaging
GmbH). High-magnification images were acquired on ei-
ther a Zeiss AxioImager.Z1 system [40/1.3 oil Plan Apo-
chromat objective; eGFP filter set (BP 470/40 for excita-
tion and BP 525/50 for emission)] or a Zeiss LSM 510
META (Axiovert 200M) confocal microscope (20/0.5
air Plan Neofluar objective, excitation at 488, emission
collected using an LP505 filter). Images depicting
hFTAA immunodouble labeling were taken with the
Zeiss LSM 510 META (Axiovert 200M) confocal micro-
scope. Laser lines 488 and 633 were used to excite
hFTAA or Alexa Fluor 633, respectively. To depict the
whole structure of interest, some images were ac-
quired as stacks, and maximum-intensity projections
are shown as indicated.
Two-Photon Imaging and Spectral Analysis
Mounted cryosections of hFTAA-injected depositing
APP23 mice and hemizygous and homozygous P301S
Tau tg mice were used for spectral analysis (for mice
details, see Results and figure legends). To be consistent
with in vivo settings/requirements, spectra were acquired
using two-photon excitation. The used TCS SP2 MP mi-croscope (Leica Microsystems, Mannheim, Germany) is
equipped with a Spectra Physics Mai-Tai laser (tunable
710 to 990 nm), which was used for two-photon excitation
at 780 nm (a pretest using different excitation wave-
lengths depicted superior excitability for hFTAA at this
wavelength). A FemtoControl pulse compressor (APE,
Berlin, Germany) was interposed in the beam path to
potentiate the probability for a two-photon excitation
event by shortening the pulse width, therefore enhanc-
ing signal intensity. For spectral imaging, the spectro-
photometer detector was used, whereby the pinhole
was completely opened. Emission scans were per-
formed with 20-nm overlapping detection ranges, re-
sulting in a final step size of 10 nm from 450 to 740 nm
(30 steps in total) using the xy mode of the Leica
confocal software (at a resolution of 256  256 pixels).
To correct for possible bleaching effects, scans were
also performed in the reverse direction (from 740 to
450 nm) and averaged afterward. Additional single-
plane images were acquired at a higher resolution
(512  512) to provide detailed morphological infor-
mation. All imaging was performed using a 40 HCX
APO water-immersion objective (0.8 numerical aper-
ture; Leica Microsystems).
Data Analysis and Statistics
Analysis of emission spectra was performed using the
multimeasure analysis tool in ImageJ version 1.44e
(http://rsbweb.nih.gov/ij, last accessed February 2012).
Regions of interest (ROIs) were drawn around hFTAA-
stained plaques, CAA, and Tau-positive cells. Single
images of the spectral emission scans were treated as
stacks, and a maximum projection was used to place
the respective ROIs. Care was taken to exclude areas
of incomplete staining and, therefore, to minimize the
contribution of autofluorescence. For Tau, additional
care was taken to exclude areas with lipofuscin auto-
fluorescence. Nevertheless, if a verifiable contribution
of lipofuscin was observed in Tau spectral profiles,
those were discarded, because this would have re-
sulted in an artificial increase of the observed spectral
shift. For each ROI, the corresponding mean gray val-
ues were measured. These data were further analyzed,
whereby for each spectrum, the minimal signal was
subtracted to exclude background signal, and the re-
sulting values were normalized to the respective max-
imum. For each lesion type and scan direction, the
mean was calculated, before averaging the values of
the two scan directions to exclude bleaching effects.
The resulting mean curves were again normalized. For
further analysis, the spectral similarity of individual
spectra was determined against the mean hFTAA
plaque spectra using the spectral angle mapper (SAM)
algorithm.25–27 Spectral similarity values of hFTAA
plaque spectra were then compared with hFTAA Tau or
CAA spectra using nonparametric statistics (U-test).
Box plot whiskers denote the 10th and 90th percen-
tiles. To visualize spectral differences within the two-
photon images, all pixels of the acquired emission
scan were assigned to a specific class (namely,
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similarity of their spectral profiles to the respective
reference spectra. A median filter of one pixel radius
was applied where deemed necessary, to remove
noisy pixels introduced by our system. Spectral simi-
larity was again determined using the SAM algorithm.
Normalization of the images was not necessary be-
cause SAM is independent of signal intensity. In detail,
we implemented the SAM algorithm in MATLAB (Math-
Works, Natick, MA), where reference spectra of two
ROIs (plaque and either Tau or CAA) obtained from the
same stack in ImageJ version 1.44e were imported
from text files. In addition, an ROI corresponding to the
background of the image was selected. The MATLAB
script loaded the spectral stack, and for each pixel, it
calculated the spectral angle (using SAM) between its
spectral profile and the reference spectra (plaque,
CAA or Tau, and background), thereby producing
three SAM values. Of these values, the highest value
was selected, which expressed the closest match to
the respective reference spectrum. In essence, this
procedure classified each pixel into one of the three
categories. A new image was generated, by which
each pixel is color coded according to the class it
belongs to (green for plaque, red for Tau or CAA, and
blue for background-like pixels). A threshold was set,
so that only the highest-scoring pixels were displayed,
and others were set to 0 (shown in black). This step is
necessary because it eliminates pixels that score low
compared with all three reference spectra, meaning
that they were noisy or non-specific or the background
had a peculiar spectral profile at that point. The thresh-
old was experimentally determined and fixed at 0.95
(ie, extremely close to the maximum similarity of 1).
Results
hFTAA Passes the BBB and Stains
Characteristic AD Lesions
Aged APP23 tg mice (n  5), 20 to 22 months old, and
symptomatic hemizygous or homozygous P301S Tau tg
mice (hemizygous: n  3, 14 to 15 months old; homozy-
gous: n  6, 6 months old) were i.v. injected with a single
dose of 20 mg/kg hFTAA (Figure 1) and analyzed 24
hours later by assessing fluorescent emission on the re-
spective brain sections. At this age, APP23 tg mice ex-
hibited A deposits in the brain parenchyma (A
plaques) and in the vasculature (CAA),22,28 whereas
P301S Tau tg mice exhibited intracellular aggregates of
hyperphosphorylated Tau.23
Histological analysis of hFTAA-injected APP23 mice
revealed homogenous labeling of A plaques and vas-
cular CAA throughout the brain. Depending on the age
of the mice, A plaques and CAA of different severity
grades were observed (Figure 2). In contrast, a cellular
staining pattern of hFTAA was observed after peripheral
hFTAA injection of hemizygous and homozygous P301S
Tau tg mice. Although symptomatic homozygous P301S
Tau tg mice depicted slightly more positive cells thansymptomatic hemizygous mice, no differences were
present with respect to the staining pattern or the mor-
phological characteristics of individual lesions. Positively
stained cells were observed primarily in the brainstem
and the amygdala, with additional staining in cortical
neurons mostly in layers II and V (Figure 2). The cellular
staining was mainly restricted to the soma and was ab-
sent in the nucleus. In some cases, protruding neurites
were also stained (Figure 2G). Overall, the fluorescent
staining distribution and morphological characteristics in
APP23 and P301S Tau tg mice closely resembled the
expected pathological characteristics previously de-
scribed using immunohistological techniques in postmor-
tem tissue.22,23,28 Non-transgenic control mice depicted
no staining after hFTAA injection (Figure 2).
To verify staining specificity at the cellular level,
sections of hFTAA-injected APP23 and P301S Tau tg
mice were postmortem labeled with antibodies directed
against A or hyperphosphorylated Tau (Figure 3). A
close match of the two signals was observed. Visual
inspection of A labeling and the hFTAA signal revealed
costaining of both A plaques and CAA (n 3 APP23 tg
mice, 21 to 22 months old). Regarding Tau lesions, the
number of double-labeled cells in the neocortex ranged
between 90% and 100% (n  4 P301S Tau tg mice;
hemizygous: n  1, 14 months old; homozygous: n  3,
6 months old; see Materials and Methods for technical
details).
In additional experiments, sections of APP23 mice
were postmortem labeled with either hFTAA or other well-
Figure 2. hFTAA passes the BBB and binds to amyloid lesions. At 24 hours
after a single i.v. injection of hFTAA, characteristic amyloid lesions are
labeled throughout the brain of transgenic mice. A: APP23 transgenic mice
depict staining of A plaques and CAA. Imagery shows hFTAA staining in
the cortex of a 21-month-old mouse. B: P301S Tau transgenic mice reveal
staining of intracellular Tau aggregates. Cortical staining shows hFTAA-
positive cells mainly in layers II and V. As one example, a 6-month-old
homozygous mouse is shown. C:Wild-type animals depict no staining. D–G:
High-magnification images of the different hFTAA-stained amyloid lesions.
hFTAA staining of A plaques (D), CAA of different severity grades (E and
F), and intracellular Tau aggregates (G). Protruding neurites are labeled
(arrowheads in G). Small punctate staining in G reflects an unspecific
autofluorescence signal of lipofuscin, a lipid degradation product frequently
present in aged brain tissue. Images in E–G are maximum-intensity projec-
tions. Scale bars: 200 m (A–C); 50 m (D and F); 20 m (E and G).known amyloid-specific dyes (Congo red, thioflavin S, or
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ing pattern of A plaques for hFTAA, methoxy-X04, and
thioflavin S. While all these dyes stained the entire amy-
loid structure, Congo red only labeled the dense core of
the A deposits. hFTAA appeared to visualize the periph-
ery of A plaques particularly well, suggesting that it also
stained diffuse amyloid.
Figure 3. IHC costaining verifies hFTAA labeling of amyloid lesions. A close
match of the hFTAA and IHC signal is observed for A plaques (A) and CAA
(B), using the A-specific antibody CN3. Imagery from an hFTAA-injected
21-month-old APP23 mouse. C: hFTAA staining shows a high portion of
overlap with Tau-positive cells identified by an antibody directed against
hyperphosphorylated Tau (AT100). Imagery from an hFTAA-injected
7-month-old homozygous P301S Tau tg mouse. Images are maximum-inten-
sity projections. Scale bar  50 m (A–C).
Figure 4. Comparison of hFTAA labeling with other amyloid-specific dyes a
an 18-month-old APP23 tg mouse. hFTAA (A), methoxy-X04 (B), and thiofl
hFTAA stains the plaque periphery particularly well. In contrast, Congo re
polarized (E) light]. F: IHC staining with an A-specific antibody (CN3) depicts labe
adjusted to ensure optimal display of stained structures regardless of differences inUsing Two-Photon Excitation hFTAA Spectrally
Discriminates Amyloid Lesions
Spectral variations were analyzed in ex vivo brain sec-
tions of hFTAA-injected APP23 and P301S Tau tg mice
using two-photon excitation at 780 nm (Figure 5; APP23
mice: n  4, 20 to 21 months old; P301S Tau mice:
hemizygous: n  2, 15 months old; homozygous: n  2,
6 months old). As no difference was observed between
spectra from hemizygous and homozygous P301S Tau tg
mice, the different genotypes were subsequently pooled.
When hFTAA-labeled Tau aggregates were compared
with hFTAA-labeled A plaques, a distinct red shift of the
hFTAA emission spectra was observed mainly within the
right shoulder (up to 20 nm; Figure 5A). In addition,
hFTAA-Tau spectra depicted a relative increase in the
second peak at approximately 590 nm. Interindividual
and intraindividual differences of hFTAA spectra ac-
quired from the two pathological conditions are depicted
in Figure 5B. Intraindividual differences of hFTAA bound
to A plaques (data from the four previously mentioned
APP23 mice; 121 plaques in total) were minor and signif-
icantly less, compared with interindividual differences of
spectra acquired from hFTAA bound to Tau aggregates
(data from the four previously mentioned Tau mice; 163
Tau lesions in total). Care was taken to exclude hFTAA
Tau spectra, which were contaminated by the presence
of lipofuscin autofluorescence (see Materials and Meth-
ods for details). Thus, using two-photon excitation and
systemic in vivo labeling, hFTAA spectrally discriminated
the two hallmark lesions of AD, A plaques and Tau
aggregates.
Next, we assessed whether hFTAA had the potential to
distinguish -amyloid subtypes. Therefore, the spectra of
hFTAA-bound A plaques were compared with the spec-
staining of A. Representative images of ex vivo–stained brain sections from
) depict labeling of A plaques, including the plaque periphery, by which
sively stains the compact plaque core [observed under transmitted (D) ornd IHC
avin S (C
d excluling of the plaque core and periphery. Filters and imaging parameters were
intensities. Scale bar  200 m.
pixels, b
1958 Wegenast-Braun et al
AJP December 2012, Vol. 181, No. 6tra of hFTAA-bound CAA in APP23 mice (data from four
APP23 mice; 121 plaques and 158 CAAs). Results re-
vealed a red shift of the emission spectra for hFTAA when
bound to CAA compared with A plaques, which was
primarily evident in the right shoulder (up to 13 nm; Figure
5D). Overall, the observed spectral differences between
CAA and A plaques were less pronounced than those
observed between A plaques and Tau lesions (Figure
5E). Nevertheless, these observations indicated that
hFTAA could not only differentiate various amyloid types
but also structural variances of the same protein.
The previously described results were collected from
either APP23 or P301S Tau tg mice to ensure the purity of
the collected spectra. To spectrally discriminate amyloid
lesions within the same mouse, APP23 tg mice were
crossed with P301S Tau tg mice to generate a model with
mixed pathological characteristics. Again, hFTAA was
injected i.v., and images containing A and Tau lesions
were captured from sections of the hFTAA-injected dou-
ble tg mice (Figure 5, C and F; n  3, 15 to 17 months
old). Differences in the spectra of the distinct pathologi-
cal conditions are displayed and color coded by a cus-
tom-made spectral classification algorithm (see Materials
and Methods for details).
Discussion
Amyloid-specific ligands constitute an indispensable set
Figure 5. hFTAA spectrally discriminates different amyloid lesions. A: The m
the mean normalized hFTAA spectrum when bound to A plaques. Analysi
Tau mice; see Results for mice details) using two-photon excitation at 780 nm
that hFTAA Tau spectra are significantly different from hFTAA plaque spectr
n  121; U-test; P  0.0001). C: Two-photon image showing an exampl
17-month-old APP23 P301S Tau double tg mouse. Spectral differences of th
algorithm (pixels with the highest similarity to the plaque reference spectr
Methods for details). D: Mean emission spectrum of hFTAA bound to CAA
the tissue of hFTAA-injected APP23 mice (n 4) using two-photon excitation
shows that hFTAA CAA spectra are significantly different from hFTAA plaqu
plaque: n  121; U-test, P  0.0001). F: Two-photon image showing an ex
Spectral differences of the two lesions are displayed via automatic categoriz
plaque reference spectra are depicted in green; CAA, red; background-like
***P  0.0001 (B and E).of tools for the diagnosis, and the investigation of pro-teopathies, including AD. Since the initial description of
the amyloid-binding dyes, Congo red and thioflavin T,4,5
many amyloidotropic dyes have been developed with
applications from basic science to clinical research. De-
spite the rapid progress in the field of in vivo amyloid
imaging, limitations remain regarding specificity to indi-
vidual amyloid types and conformational variants. In par-
ticular, cerebral proteopathies mostly consist of a mixture
of various amyloids,3 and dyes that can discriminate be-
tween such lesions and their conformational variants are
of enormous diagnostic value and essential for studying
disease pathomechanisms.
LCOs have unique optical properties, because they
exhibit spectral changes when binding to distinct amyloid
types.18 The aim of the present study was to advance the
use of LCOs to in vivo applications. The respective re-
quirements were that the dye is able to do the following:
i) pass the BBB, ii) bind amyloid lesions after peripheral
application, and iii) exhibit lesion- and conformation-spe-
cific spectral shifts on two-photon excitation.
Herein, we have demonstrated that the heptameric
LCO hFTAA fulfills all of these prerequisites when tested
in mouse models of AD. After a single systemic injection,
hFTAA crossed the BBB and specifically stained A
plaques, CAA, and intracellular Tau lesions. Because
the periphery of A plaques was particularly well labeled
with hFTAA, we expect that diffuse amyloid is also
stained by hFTAA. This observation is consistent with a
rmalized emission spectrum of hFTAA bound to Tau aggregates differs from
ormed on tissue of hFTAA-injected mice (n  4 for both APP23 and P301S
lysis of spectral similarity using the spectral angle mapper algorithm reveals
ously mentioned mice; hFTAA spectra Tau: n  163; hFTAA spectra plaque:
ighboring hFTAA-stained Tau (arrow) and A plaque (arrowhead) in a
sions are displayed via automatic classification by the spectral angle mapper
picted in green; Tau, red; background-like pixels, blue; see Materials and
rom mean hFTAA spectrum bound to A plaques. Analysis is performed on
m. E: Analysis of spectral similarity using the spectral angle mapper algorithm
(previously mentioned mice; hFTAA spectra CAA: n 158; hFTAA spectra
f neighboring hFTAA-stained CAA (arrow) and A plaque (arrowhead).
th the spectral angle mapper algorithm (pixels with highest similarity to the











ation wirecent study29 in which, and in contrast to thioflavin T, the
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amyloid deposits in the striatum of bitransgenic ArcSwe 
tg-Swe mice. Notably, several LCOs, including hFTAA,
also detected non-thioflavinophilic prefibrillar amyloid
species in vitro,20 demonstrating that LCOs have the
potential to visualize protein aggregates that are not
detected by classic amyloid-specific dyes, such as
thioflavin T.
In addition to the in vivo labeling of all major AD patho-
logical characteristics, hFTAA allowed the spectral discrim-
ination of the amyloid lesions on two-photon excitation, al-
beit demonstrated in ex vivo tissue. In vivo two-photon
spectral imaging is limited by the lack of commercially avail-
able spectral detectors that are optimized for in vivo appli-
cations (ie, the current detectors lack the required sensitiv-
ity). However, new customized spectral detectors are
developed, which will offer improved sensitivity and allow
spectral analysis of different amyloid lesions in vivo.
The spectral shift of hFTAA bound to Tau versus A
plaques observed in the present article is similar to the
spectral shift using single-photon excitation previously
reported by Klingstedt et al.20 In the latter study, pFTAA
depicted an even bigger spectral shift between the two
pathological features, but only when combining emission
spectra acquired with two different excitation wave-
lengths. Because we focused on the usability for in vivo
application, sequential excitation with different wave-
lengths was not deemed practical (eg, because of en-
hanced phototoxicity).
Amyloidotrophic dyes potentially interfere with amyloid
growth. In PS1/APP tg mice, methoxy-X04 has interfered
with A plaque formation, albeit in higher doses, as nor-
mally used for imaging (20 mg/kg, treatment from the age
of 9 weeks, three times a week, nine treatments in total).31
Therefore, it is of specific interest that the persistent treat-
ment with the pentameric oligothiophene pFTAA revealed
no effect on A load in APPPS1 tg mice (10 mg/kg, four
initial daily injections, followed by weekly injections from
the age of 42 to 120 days)32 and in APP23 tg mice (10
mg/kg, two initial daily injections, followed by biweekly
injections from the age of 6 to 13 months; own unpub-
lished data). Furthermore, no signs of toxicity were ob-
served with respect to body weight, differential blood cell
counts, and histological analyses of peripheral organs.32
Assuming analogy with its heptameric form, these results
emphasize the suitability of hFTAA as a long-term in vivo
imaging probe. This observation also suggests that
pFTAA (and presumably hFTAA) binds to the amyloid
backbone and does not interfere with the growth of the
steric zipper.3
There are multiple lines of evidence that amyloid le-
sions in the brain are structurally diverse, ranging from
different A plaque morphotypes and Tau inclusion bod-
ies to various soluble structurally distinct oligomeric spe-
cies with presumably different biological activities.3,33
Thus, by introducing different mouse models and age
groups, future studies will assess whether hFTAA is also
effective in distinguishing these conformational variants
and whether changes in amyloid composition/structure
can be visualized with disease progression in the living
organism.The present study establishes the baseline for such
future intravital applications. Herein, we describe, for the
first time to our knowledge, a conformation-sensitive dye,
which, on peripheral application, labels extracellular
plaques, CAA, and intracellular Tau lesions. Further-
more, we demonstrated that these different amyloid le-
sions can be spectrally discriminated using two-photon
excitation, thus paving the way for in vivo spectral imag-
ing and differentiation of amyloid lesions over time. The
effective separation of amyloid (sub) types may allow for
the linkage of distinct conformational amyloid structures
to in vivo malfunctions.
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